MX2018003215A - Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2. - Google Patents

Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.

Info

Publication number
MX2018003215A
MX2018003215A MX2018003215A MX2018003215A MX2018003215A MX 2018003215 A MX2018003215 A MX 2018003215A MX 2018003215 A MX2018003215 A MX 2018003215A MX 2018003215 A MX2018003215 A MX 2018003215A MX 2018003215 A MX2018003215 A MX 2018003215A
Authority
MX
Mexico
Prior art keywords
imidazo
quinoline
naphthyridine derivatives
novel
disease
Prior art date
Application number
MX2018003215A
Other languages
English (en)
Inventor
Paul Galatsis
Travis T Wager
Patrick Robert Verhoest
Bethany Lyn Kormos
Ravi G Kurumbail
Antonia Friederike Stepan
Martin Youngjin Pettersson
Louise Henderson Jaclyn
Richard REESE Matthew
Renee Garnsey Michelle
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2018003215A publication Critical patent/MX2018003215A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención proporciona derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftiridina novedosos de la Fórmula (I), y las sales farmacéuticamente aceptables de los mismos (ver Fórmula) en donde R1, R1a, R1b, R2, R4, R5, R6, X y Z son como se define en la especificación. La invención también se dirige a composiciones farmacéuticas que comprenden los compuestos de la Fórmula (I) y el uso de los compuestos en el tratamiento de enfermedades asociadas con LRRK2, tales como enfermedades neurodegenerativas incluyendo enfermedad de Parkinson o enfermedad de Alzheimer, cáncer, enfermedad de Crohn o lepra.
MX2018003215A 2015-09-14 2016-09-07 Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2. MX2018003215A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562218061P 2015-09-14 2015-09-14
US201662375646P 2016-08-16 2016-08-16
PCT/IB2016/055328 WO2017046675A1 (en) 2015-09-14 2016-09-07 Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors

Publications (1)

Publication Number Publication Date
MX2018003215A true MX2018003215A (es) 2018-06-08

Family

ID=56940107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003215A MX2018003215A (es) 2015-09-14 2016-09-07 Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.

Country Status (13)

Country Link
US (1) US10039753B2 (es)
EP (1) EP3350178B1 (es)
JP (1) JP6873980B2 (es)
KR (1) KR102161364B1 (es)
CN (1) CN108137586B (es)
AU (2) AU2016322813B2 (es)
CA (1) CA2941408A1 (es)
HK (1) HK1258857A1 (es)
IL (1) IL257886B (es)
MX (1) MX2018003215A (es)
RU (1) RU2722149C1 (es)
TW (1) TWI639595B (es)
WO (1) WO2017046675A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
CA3025672A1 (en) 2016-06-16 2017-12-21 Denali Therapeutics Inc. Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
JP7011764B2 (ja) 2016-07-07 2022-01-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗体アジュバント複合体
WO2018163030A1 (en) * 2017-03-10 2018-09-13 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
CA3056030A1 (en) * 2017-03-10 2018-09-13 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019177971A1 (en) * 2018-03-12 2019-09-19 Mavupharma, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
CN108822119B (zh) * 2018-06-25 2020-08-28 中国医学科学院医药生物技术研究所 具有自噬激活活性的红醇酮类化合物、其制备方法及其制药应用
MX2021001376A (es) * 2018-08-09 2021-06-23 Valo Early Discovery Inc Carboxamidas como inhibidores de proteasa específicos de ubiquitina.
CN112996567A (zh) * 2018-08-16 2021-06-18 先天肿瘤免疫公司 咪唑并[4,5-c]喹啉衍生的nlrp3-调节剂
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2024008113A1 (zh) * 2022-07-07 2024-01-11 深圳微芯生物科技股份有限公司 一种甲酰胺取代的杂三环类衍生物、其制备方法及其应用

Family Cites Families (231)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
JP2890448B2 (ja) 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
CA2011504C (en) * 1989-03-07 1998-06-02 Kenji Ohmori Imidazoquinolone derivatives
JP2988683B2 (ja) * 1989-03-07 1999-12-13 協和醗酵工業株式会社 イミダゾキノロン誘導体
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5763597A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
US5795977A (en) 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
JPH03271289A (ja) 1990-03-16 1991-12-03 Nissan Chem Ind Ltd ピラゾロピリジン誘導体の製造法及びジヒドロピラゾロピリジン誘導体
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
ES2186034T3 (es) * 1991-03-01 2003-05-01 Minnesota Mining & Mfg Intermedios para la preparacion de 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas, 2-sustituidas.
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP3130342B2 (ja) 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
JP3271289B2 (ja) 1992-02-28 2002-04-02 スズキ株式会社 ４サイクルエンジンのバルブ駆動装置
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
CA2130937A1 (en) 1992-04-03 1993-10-14 Gordon L. Bundy Pharmaceutically active bicyclic-heterocyclic amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
WO1995011898A1 (en) 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
JPH05310700A (ja) 1992-05-12 1993-11-22 Sagami Chem Res Center 縮合ピリジン系メバロノラクトン中間体及びその製法
JPH0641114A (ja) 1992-05-25 1994-02-15 Nissan Chem Ind Ltd 新規メバロノラクトン類とその製法
US6608201B2 (en) * 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JPH06116239A (ja) 1992-10-05 1994-04-26 Nissan Chem Ind Ltd ７−置換−３，５−ジヒドロキシヘプタ−６−イン酸類
KR950703537A (ko) 1992-10-16 1995-09-20 시모무라 도오루 피리미딘 유도체(pyrimidine derivative)
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
WO1994018215A1 (en) 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
JP3350739B2 (ja) 1993-06-10 2002-11-25 コニカ株式会社 黒白ハロゲン化銀写真感光材料の現像処理方法
CN1102644A (zh) 1993-11-11 1995-05-17 财团法人相模中央化学研究所 缩合吡啶型甲羟戊酸内酯中间体及其制备方法
JPH07281365A (ja) 1994-04-07 1995-10-27 Konica Corp 写真感光材料の処理方法
ATE159257T1 (de) 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
JP3448724B2 (ja) 1995-11-29 2003-09-22 コニカ株式会社 ハロゲン化銀写真感光材料用現像剤及びその処理方法
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
DK0888353T3 (da) 1996-03-15 2003-10-27 Novartis Ag N-7-Heterocyclyl-pyrrolo[2,3-d]pyrimidiner og deres anvendelse
JPH10213887A (ja) 1996-11-26 1998-08-11 Konica Corp 黒白ハロゲン化銀写真感光材料の処理方法
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
EP0846981A1 (en) 1996-12-03 1998-06-10 Konica Corporation Method for processing black-and-white silver halide photographic light-sensitive material
JP3543249B2 (ja) 1996-12-18 2004-07-14 コニカミノルタホールディングス株式会社 黒白ハロゲン化銀写真感光材料の処理方法
JP4101302B2 (ja) * 1997-01-09 2008-06-18 テルモ株式会社 新規アミド誘導体および合成中間体
ATE402717T1 (de) 1997-04-09 2008-08-15 Intellect Neurosciences Inc Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
TR200003719T2 (tr) 1998-06-19 2001-03-21 Pfizer Products Inc. Pirolo[2,3-d]Pirimidin bileşikleri
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6125627A (en) 1998-08-11 2000-10-03 Allison Advanced Development Company Method and apparatus for spraying fuel within a gas turbine engine
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6309811B2 (en) 1999-07-21 2001-10-30 Eastman Kodak Company Color photographic element containing nitrogen heterocycle derivative and inhibitor releasing coupler
KR100767146B1 (ko) 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
AU2001264313A1 (en) 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
CA2427661C (en) 2000-11-03 2013-05-28 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
UA75622C2 (en) * 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
ATE368658T1 (de) 2000-12-22 2007-08-15 Wyeth Corp Hetorocyclindazole und -azaindazole verbindungen als 5-hydroxytryptamine-6 liganden
US20040192889A1 (en) 2001-03-30 2004-09-30 Dale Bredesen Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
BR0212619A (pt) 2001-09-20 2004-08-17 Glaxo Group Ltd Sequência de nucleotìdeo, vetor, proteìna, composição farmacêutica, dispositivo de liberação intradérmica, método para tratar um paciente que sofre de uma doença ou é suscetìvel a ela, uso de uma sequência de nucleotìdeo, e, processo para a produção de um nucleotìdeo
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
AU2002339230A1 (en) 2002-03-08 2003-09-22 Decode Genetics Ehf. A susceptibility gene for late-onset idiopathic parkinson's disease
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
AU2003299863B2 (en) 2002-08-15 2009-09-24 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
PL377769A1 (pl) 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
DE10259382A1 (de) 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
MXPA05006740A (es) * 2002-12-20 2005-10-05 3M Innovative Properties Co Imidazoquinolinas arilo-sustituidas.
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004110996A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
MY157827A (en) 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
ES2406730T3 (es) 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
EP1673087B1 (en) * 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
AU2004291122A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
WO2005048933A2 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
WO2005062795A2 (en) 2003-12-19 2005-07-14 Plexxikon, Inc. Compounds and methods for development of ret modulators
US7888349B2 (en) * 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
US8735421B2 (en) * 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
US20050153989A1 (en) 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CA2555071A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
CN1960969B (zh) 2004-04-01 2012-03-28 伊莱利利公司 组胺h3受体药物、其制备方法及治疗用途
JP5019612B2 (ja) 2004-04-02 2012-09-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｒｏｃｋの阻害剤として有用なアザインドールおよび他のプロテインキナーゼ
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
EP1773880A4 (en) 2004-06-08 2009-09-09 Novartis Vaccines & Diagnostic ENV POLYPEPTIDE COMPLEXES AND METHOD FOR THEIR USE
WO2005123079A2 (en) 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006009832A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
CA2572314A1 (en) 2004-06-29 2006-01-12 Christopher N. Farthing Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity
CA2575663C (en) 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
BRPI0515316A (pt) * 2004-09-14 2008-07-15 Chiron Corp compostos de imidazoquinolina
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US8029986B2 (en) 2004-10-21 2011-10-04 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt(GmbH) KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders
US7511056B2 (en) 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
EP1827493A4 (en) 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR TREATING TRAUMATIC BRAIN INJURY
JP2008531568A (ja) * 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキルで置換されたイミダゾナフチリジン
JP2008543725A (ja) * 2005-02-23 2008-12-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン
CA2598437A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
WO2006121528A2 (en) * 2005-04-01 2006-11-16 Coley Pharmaceutical Group, Inc. Ring closing and related methods and intermediates
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
CA2607499C (en) 2005-06-22 2010-11-30 Pfizer Products Inc. Histamine-3 receptor antagonists
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
JP2009521504A (ja) 2005-12-22 2009-06-04 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性阻害剤
WO2007076348A2 (en) 2005-12-23 2007-07-05 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
CA2645214A1 (en) 2006-03-14 2007-09-20 Cellzome Ag Methods for the identification of lrrk2 interacting molecules and for the purification of lrrk2
WO2007124096A2 (en) 2006-04-21 2007-11-01 The Trustees Of Columbia University In The City Of New York Lrrk2 regulaton of neuronal process morphology
GB0610317D0 (en) 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
WO2007143526A2 (en) * 2006-06-05 2007-12-13 Coley Pharmaceutical Group, Inc. Substituted tetrahydroimidazonaphthyridines and methods
JP2009541336A (ja) 2006-06-20 2009-11-26 ノバルティス アクチエンゲゼルシャフト アルツハイマー病の進行に関するバイオマーカー
US8466163B2 (en) 2006-12-11 2013-06-18 Bionomics Limited Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
WO2008091799A2 (en) 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
PL2124933T3 (pl) 2007-01-22 2013-02-28 Pfizer Prod Inc Sól tosylanowa związku terapeutycznego i jej kompozycje farmaceutyczne
FR2912744B1 (fr) 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
GB0706709D0 (en) 2007-04-05 2007-05-16 Medical Res Council Methods
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
ME00954B (me) 2007-05-11 2012-06-20 Pfizer Aminoheterociklični spojevi
CL2008001540A1 (es) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
WO2009005730A1 (en) 2007-06-27 2009-01-08 Cornell University Transgenic animal models of parkinson's disease
WO2009030270A1 (en) 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
AU2008297814A1 (en) 2007-09-14 2009-03-19 Sanofi-Aventis 3-Methyl-2- ( (2S) -2- (4- (3-Methyl-1, 2, 4-Oxadiazol-5-YL) phenyl) morpholino) -6- (pyrimidin-4-yl) Pyrimidin-4 (3H) -one as tau protein kinase inhibitor
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
CA2707554C (en) 2007-12-05 2015-06-30 Gerd Dannhardt Use of 3-(indolyl)-or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
CA2723185A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
JP5502072B2 (ja) 2008-04-30 2014-05-28 ナショナル ヘルス リサーチ インスティテューツ オーロラキナーゼ阻害剤としての縮合二環式ピリミジン化合物
DE102008025751A1 (de) 2008-05-29 2009-12-03 Merck Patent Gmbh 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
CN102143746A (zh) 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
DE102008031517A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
FR2935712A1 (fr) 2008-09-05 2010-03-12 Ct Hospitalier Regional Univer Methode de detection de l'expression differentielle d'un ensemble de marqueurs moleculaires associee a la maladie de parkinson
GB2463656B (en) 2008-09-18 2010-10-13 Medical Res Council Substrate of LRRK2 and methods of assessing LRRK2 activity
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
US20100175140A1 (en) 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies
WO2010080712A2 (en) 2009-01-06 2010-07-15 Dana Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP2210887A1 (en) 2009-01-14 2010-07-28 Isdin, S.A. Bis resorcinyl triazine derivatives as protecting agents against UV radiation
WO2010085799A2 (en) 2009-01-26 2010-07-29 Tautatis, Inc. Compositions and method for the treatment of parkinson's disease
KR20100092909A (ko) 2009-02-13 2010-08-23 주식회사 엘지생명과학 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
MX2011009807A (es) 2009-03-19 2011-09-29 Medical Res Council Technology Compuestos.
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
KR20100116765A (ko) 2009-04-23 2010-11-02 인제대학교 산학협력단 파킨슨병 치료제 스크리닝 방법
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
SG179120A1 (en) 2009-09-29 2012-05-30 Glaxo Group Ltd Novel compounds
LT2485731T (lt) * 2009-10-06 2016-09-12 Millennium Pharmaceuticals, Inc. Heterocikliniai junginiai, tinkami naudoti kaip pdk1 inhibitoriai
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
WO2011049827A1 (en) 2009-10-19 2011-04-28 Coates Fredrica V Undergarment with hidden core pocket with isolating fluid layer
DE102009051204A1 (de) 2009-10-29 2011-05-19 Muller, Katherina Elektro-Hydraulischer Fahrantrieb für Kraftfahrzeuge
WO2011053861A1 (en) 2009-10-29 2011-05-05 Genosco Kinase inhibitors
KR20110049217A (ko) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
WO2011057204A2 (en) 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
KR101663637B1 (ko) 2009-11-13 2016-10-07 제노스코 키나아제 억제제
JP2013512859A (ja) * 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
EP2338486A1 (en) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
CA2986631C (en) 2009-12-21 2020-06-02 Samumed, Llc 1h-pyrazolo[3,4-.beta.]pyridines and thereapeutic uses thereof
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
US8367349B2 (en) 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2
US20130040933A1 (en) 2010-04-27 2013-02-14 Brandon Cash Azaindoles as janus kinase inhibitors
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
WO2011144622A1 (en) * 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh 1h - imidazo [4, 5 - c] quinolines
US9303322B2 (en) 2010-05-24 2016-04-05 Integran Technologies Inc. Metallic articles with hydrophobic surfaces
KR101208198B1 (ko) 2010-08-27 2012-12-04 인제대학교 산학협력단 Ｌｒｒｋ２ 인산화효소 억제 활성을 갖는 화합물을 유효성분으로 함유하는 파킨슨병 치료 또는 예방용 약학조성물
US9365551B2 (en) 2010-09-02 2016-06-14 Glaxo Group Limited 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors
WO2012034526A1 (en) * 2010-09-16 2012-03-22 Hutchison Medipharma Limited Fused heteroaryls and their uses
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JP5310700B2 (ja) 2010-10-27 2013-10-09 パナソニック株式会社 Ｌｅｄパッケージ製造システムおよびｌｅｄパッケージ製造システムにおける樹脂塗布方法
WO2012058193A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
BR112013013457A2 (pt) 2010-11-30 2017-07-11 Genentech Inc métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições
US20130338106A1 (en) 2011-02-28 2013-12-19 John A. McCauley Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9493452B2 (en) 2011-03-24 2016-11-15 Southern Methodist University Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
GB201105137D0 (en) 2011-03-28 2011-05-11 Isis Innovation Therapeutic molecules for use in the suppression of Parkinson's disease
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
EP2694509B1 (en) 2011-04-05 2016-05-18 Pfizer Limited Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
KR101649610B1 (ko) * 2011-04-21 2016-08-19 오리제니스 게엠베하 키나아제 억제제로서의 헤테로사이클릭 화합물
WO2012143144A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
EP2710041A4 (en) 2011-05-18 2014-11-05 Parkinson S Inst ASSAY FOR DETERMINING LRRK2 ACTIVITY IN MORBUS PARKINSON
CA2837199A1 (en) 2011-05-23 2012-11-29 Elan Pharmaceuticals, Inc. Cinnoline compounds as inhibitor of lrrk2 kinase activity
WO2012178015A2 (en) 2011-06-24 2012-12-27 Zenobia Therapeutics, Inc. Lrrk2 inhibitors
WO2013007768A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
US9096609B2 (en) 2011-09-30 2015-08-04 Ipsen Pharma S.A.S. Macrocyclic LRRK2 kinase inhibitors
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
EP2844660B1 (en) 2012-05-02 2017-11-01 Southern Research Institute Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
KR102091894B1 (ko) 2012-05-03 2020-03-20 제넨테크, 인크. Lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
WO2014001973A1 (en) 2012-06-29 2014-01-03 Pfizer Inc. NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
CA2885253A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
WO2014060113A1 (en) * 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
JP6116239B2 (ja) 2012-12-28 2017-04-19 キヤノン株式会社 被検体情報取得装置および被検体情報取得方法
JP6041114B2 (ja) 2013-03-21 2016-12-07 ▲華▼▲為▼▲終▼端有限公司 データ送信方法、基地局、及びユーザ装置
ITTO20130694A1 (it) 2013-08-14 2015-02-15 Umbra Meccanotecnica Giunto washpipe per un impianto di perforazione petrolifera
WO2015022664A1 (en) * 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
JP2017502068A (ja) 2014-01-10 2017-01-19 シャンハイ バーディー バイオテック インコーポレイテッド Ｈｅｒ２陽性腫瘍を処置するための化合物及び組成物
US11497586B2 (en) 2014-03-21 2022-11-15 Align Technology, Inc. Segmented orthodontic appliance with elastics
JP6247966B2 (ja) 2014-03-13 2017-12-13 シャープ株式会社 商品販売登録装置
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
EP4001311A1 (en) 2014-07-09 2022-05-25 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于***的抗-pd-l1结合物

Also Published As

Publication number Publication date
IL257886A (en) 2018-06-03
WO2017046675A1 (en) 2017-03-23
CN108137586A (zh) 2018-06-08
AU2021201608A1 (en) 2021-04-08
JP6873980B2 (ja) 2021-05-19
AU2016322813A1 (en) 2018-03-29
IL257886B (en) 2021-10-31
CN108137586B (zh) 2021-04-13
EP3350178A1 (en) 2018-07-25
TW201722945A (zh) 2017-07-01
TWI639595B (zh) 2018-11-01
KR20180050407A (ko) 2018-05-14
AU2016322813B2 (en) 2021-04-01
EP3350178B1 (en) 2021-10-20
KR102161364B1 (ko) 2020-09-29
RU2722149C1 (ru) 2020-05-27
KR102161364B9 (ko) 2024-03-11
CA2941408A1 (en) 2017-03-14
HK1258857A1 (zh) 2019-11-22
US10039753B2 (en) 2018-08-07
JP2018526422A (ja) 2018-09-13
US20170073343A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
MX2018003215A (es) Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
PH12014502886A1 (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MD4779B1 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MD4575C1 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
GEP20207172B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
TN2015000005A1 (en) Azaindole derivatives which act as pi3k inhibitors
MX369952B (es) Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1.
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
MX2019010756A (es) Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
TW201613864A (en) Novel compounds
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
MX2018004517A (es) Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak).
WO2016051306A3 (en) Novel anthranilic acid derivatives
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
PH12016501645A1 (en) Aminopyrazolone derivative
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases

Legal Events

Date Code Title Description
FG Grant or registration